Bio Techne Corp Stock Net Income
| TECH Stock | USD 57.44 0.43 0.74% |
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess Bio Techne's long-term financial health and intrinsic value.
| Last Reported | Projected for Next Year | ||
| Net Income | 193.3 M | 202.9 M | |
| Net Income Applicable To Common Shares | 328.1 M | 344.5 M | |
| Net Income From Continuing Ops | 193.3 M | 160.6 M | |
| Net Income Per Share | 0.96 | 1.01 | |
| Net Income Per E B T | 0.81 | 0.58 |
Bio | Net Income | Build AI portfolio with Bio Stock |
Bio Techne Corp Company Net Income Analysis
Bio Techne's Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Bio Techne Net Income | 168.07 M |
Most of Bio Techne's fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Bio Techne Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Bio Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Bio Techne is extremely important. It helps to project a fair market value of Bio Stock properly, considering its historical fundamentals such as Net Income. Since Bio Techne's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Bio Techne's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Bio Techne's interrelated accounts and indicators.
Bio Net Income Historical Pattern
Today, most investors in Bio Techne Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Bio Techne's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's net income growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Bio Techne net income as a starting point in their analysis.
Bio Techne Net Income |
| Timeline |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Bio Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Bio Techne Corp reported net income of 168.07 M. This is 50.75% lower than that of the Life Sciences Tools & Services sector and 139.95% higher than that of the Health Care industry. The net income for all United States stocks is 70.56% higher than that of the company.
Bio Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Bio Techne's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Bio Techne could also be used in its relative valuation, which is a method of valuing Bio Techne by comparing valuation metrics of similar companies.Bio Techne is currently under evaluation in net income category among its peers.
Bio Techne ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Bio Techne's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Bio Techne's managers, analysts, and investors.Environmental | Governance | Social |
Bio Techne Institutional Holders
Institutional Holdings refers to the ownership stake in Bio Techne that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Bio Techne's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Bio Techne's value.| Shares | Massachusetts Financial Services Company | 2025-03-31 | 3 M | Df Dent & Co Inc | 2025-03-31 | 2.9 M | Mairs & Power Inc | 2025-03-31 | 2.7 M | Mackenzie Investments | 2025-03-31 | 2.5 M | Champlain Investment Partners, Llc | 2025-03-31 | 2.4 M | Bank Of New York Mellon Corp | 2025-03-31 | 2.4 M | Macquarie Group Ltd | 2025-03-31 | 2.1 M | Sumitomo Mitsui Trust Group Inc | 2025-03-31 | 2 M | Brown Advisory Holdings Inc | 2025-03-31 | 1.9 M | Vanguard Group Inc | 2025-03-31 | 18.5 M | Blackrock Inc | 2025-03-31 | 13.7 M |
Bio Fundamentals
| Return On Equity | 0.0653 | ||||
| Return On Asset | 0.0524 | ||||
| Profit Margin | 0.11 % | ||||
| Operating Margin | 0.14 % | ||||
| Current Valuation | 9.46 B | ||||
| Shares Outstanding | 156.77 M | ||||
| Shares Owned By Insiders | 1.06 % | ||||
| Shares Owned By Institutions | 98.94 % | ||||
| Number Of Shares Shorted | 6.53 M | ||||
| Price To Earning | 74.38 X | ||||
| Price To Book | 4.55 X | ||||
| Price To Sales | 7.59 X | ||||
| Revenue | 1.16 B | ||||
| Gross Profit | 801.67 M | ||||
| EBITDA | 310.37 M | ||||
| Net Income | 168.07 M | ||||
| Cash And Equivalents | 247.03 M | ||||
| Cash Per Share | 6.30 X | ||||
| Total Debt | 419.54 M | ||||
| Debt To Equity | 0.19 % | ||||
| Current Ratio | 3.44 X | ||||
| Book Value Per Share | 12.87 X | ||||
| Cash Flow From Operations | 298.98 M | ||||
| Short Ratio | 3.32 X | ||||
| Earnings Per Share | 0.83 X | ||||
| Price To Earnings To Growth | 1.60 X | ||||
| Target Price | 66.0 | ||||
| Number Of Employees | 3.1 K | ||||
| Beta | 1.38 | ||||
| Market Capitalization | 9.18 B | ||||
| Total Asset | 2.7 B | ||||
| Retained Earnings | 1.33 B | ||||
| Working Capital | 458.04 M | ||||
| Current Asset | 253.89 M | ||||
| Current Liabilities | 54.15 M | ||||
| Annual Yield | 0.01 % | ||||
| Five Year Return | 0.56 % | ||||
| Net Asset | 2.7 B | ||||
| Last Dividend Paid | 0.32 |
About Bio Techne Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Bio Techne Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bio Techne using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bio Techne Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| USOI | Credit Suisse X Links | |
| ULTY | Tidal Trust II | |
| CONY | YieldMax N Option | |
| BCAT | BlackRock Capital Allocation | |
| PDI | Pimco Dynamic Income |
Check out Bio Techne Piotroski F Score and Bio Techne Altman Z Score analysis. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bio Techne. If investors know Bio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bio Techne listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.55) | Dividend Share 0.32 | Earnings Share 0.83 | Revenue Per Share | Quarterly Revenue Growth 0.042 |
The market value of Bio Techne Corp is measured differently than its book value, which is the value of Bio that is recorded on the company's balance sheet. Investors also form their own opinion of Bio Techne's value that differs from its market value or its book value, called intrinsic value, which is Bio Techne's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bio Techne's market value can be influenced by many factors that don't directly affect Bio Techne's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bio Techne's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bio Techne is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bio Techne's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.